575 related articles for article (PubMed ID: 27018857)
1. Comparative efficacy of tocilizumab, abatacept and rituximab after non-TNF inhibitor failure: results from a multicentre study.
Pascart T; Philippe P; Drumez E; Deprez X; Cortet B; Duhamel A; Houvenagel E; Flipo RM
Int J Rheum Dis; 2016 Nov; 19(11):1093-1102. PubMed ID: 27018857
[TBL] [Abstract][Full Text] [Related]
2. Comparative efficacy and safety of tocilizumab, rituximab, abatacept and tofacitinib in patients with active rheumatoid arthritis that inadequately responds to tumor necrosis factor inhibitors: a Bayesian network meta-analysis of randomized controlled trials.
Lee YH; Bae SC
Int J Rheum Dis; 2016 Nov; 19(11):1103-1111. PubMed ID: 26692536
[TBL] [Abstract][Full Text] [Related]
3. Real-world experience of tocilizumab in rheumatoid arthritis: sub-analysis of data from the Italian biologics' register GISEA.
Iannone F; Ferraccioli G; Sinigaglia L; Favalli EG; Sarzi-Puttini P; Atzeni F; Gorla R; Bazzani C; Govoni M; Farina I; Gremese E; Carletto A; Giollo A; Galeazzi M; Foti R; Bianchino L; La Grasta L; Lapadula G
Clin Rheumatol; 2018 Feb; 37(2):315-321. PubMed ID: 28980085
[TBL] [Abstract][Full Text] [Related]
4. Malignant Neoplasms in Patients With Rheumatoid Arthritis Treated With Tumor Necrosis Factor Inhibitors, Tocilizumab, Abatacept, or Rituximab in Clinical Practice: A Nationwide Cohort Study From Sweden.
Wadström H; Frisell T; Askling J;
JAMA Intern Med; 2017 Nov; 177(11):1605-1612. PubMed ID: 28975211
[TBL] [Abstract][Full Text] [Related]
5. Treatment of Rheumatoid Arthritis With Anti-Tumor Necrosis Factor or Tocilizumab Therapy as First Biologic Agent in a Global Comparative Observational Study.
Choy EH; Bernasconi C; Aassi M; Molina JF; Epis OM
Arthritis Care Res (Hoboken); 2017 Oct; 69(10):1484-1494. PubMed ID: 28622454
[TBL] [Abstract][Full Text] [Related]
6. Brief Report: Risk of Gastrointestinal Perforation Among Rheumatoid Arthritis Patients Receiving Tofacitinib, Tocilizumab, or Other Biologic Treatments.
Xie F; Yun H; Bernatsky S; Curtis JR
Arthritis Rheumatol; 2016 Nov; 68(11):2612-2617. PubMed ID: 27213279
[TBL] [Abstract][Full Text] [Related]
7. Patient characteristics influence the choice of biological drug in RA, and will make non-TNFi biologics appear more harmful than TNFi biologics.
Frisell T; Baecklund E; Bengtsson K; Di Giuseppe D; Forsblad-d'Elia H; Askling J;
Ann Rheum Dis; 2018 May; 77(5):650-657. PubMed ID: 29237621
[TBL] [Abstract][Full Text] [Related]
8. Survival on treatment with second-line biologic therapy: a cohort study comparing cycling and swap strategies.
Favalli EG; Biggioggero M; Marchesoni A; Meroni PL
Rheumatology (Oxford); 2014 Sep; 53(9):1664-8. PubMed ID: 24729445
[TBL] [Abstract][Full Text] [Related]
9. Alternative tumour necrosis factor inhibitors (TNFi) or abatacept or rituximab following failure of initial TNFi in rheumatoid arthritis: the SWITCH RCT.
Brown S; Everett CC; Naraghi K; Davies C; Dawkins B; Hulme C; McCabe C; Pavitt S; Emery P; Sharples L; Buch MH
Health Technol Assess; 2018 Jun; 22(34):1-280. PubMed ID: 29900829
[TBL] [Abstract][Full Text] [Related]
10. Overall infection risk in rheumatoid arthritis during treatment with abatacept, rituximab and tocilizumab; an observational cohort study.
Grøn KL; Glintborg B; Nørgaard M; Mehnert F; Østergaard M; Dreyer L; Krogh NS; Hetland ML
Rheumatology (Oxford); 2020 Aug; 59(8):1949-1956. PubMed ID: 31764977
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of abatacept and tocilizumab in patients with rheumatoid arthritis treated in clinical practice: results from the nationwide Danish DANBIO registry.
Leffers HC; Ostergaard M; Glintborg B; Krogh NS; Foged H; Tarp U; Lorenzen T; Hansen A; Hansen MS; Jacobsen MS; Dreyer L; Hetland ML;
Ann Rheum Dis; 2011 Jul; 70(7):1216-22. PubMed ID: 21551512
[TBL] [Abstract][Full Text] [Related]
12. Comparative effectiveness of rituximab, abatacept, and tocilizumab in adults with rheumatoid arthritis and inadequate response to TNF inhibitors: prospective cohort study.
Gottenberg JE; Morel J; Perrodeau E; Bardin T; Combe B; Dougados M; Flipo RM; Saraux A; Schaeverbeke T; Sibilia J; Soubrier M; Vittecoq O; Baron G; Constantin A; Ravaud P; Mariette X;
BMJ; 2019 Jan; 364():l67. PubMed ID: 30679233
[TBL] [Abstract][Full Text] [Related]
13. Infliximab equivalently suppresses oxidative stress compared to tocilizumab among well-controlled patients with rheumatoid arthritis.
Kizaki K; Yamashita F; Hayashi T; Funakoshi N
Int J Rheum Dis; 2018 Oct; 21(10):1815-1821. PubMed ID: 27778459
[TBL] [Abstract][Full Text] [Related]
14. The Impact of Newer Biological Disease Modifying Anti-Rheumatic Drugs on Cardiovascular Risk Factors: A 12-Month Longitudinal Study in Rheumatoid Arthritis Patients Treated with Rituximab, Abatacept and Tociliziumab.
Provan SA; Berg IJ; Hammer HB; Mathiessen A; Kvien TK; Semb AG
PLoS One; 2015; 10(6):e0130709. PubMed ID: 26114946
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of tocilizumab in refractory rheumatoid arthritis: a real life cohort from a single centre.
Addimanda O; Possemato N; Macchioni P; Salvarani C
Clin Exp Rheumatol; 2014; 32(4):460-4. PubMed ID: 24960220
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of abatacept, rituximab, and TNFi treatment after previous failure with TNFi treatment in rheumatoid arthritis: a pragmatic multi-centre randomised trial.
Manders SH; Kievit W; Adang E; Brus HL; Moens HJ; Hartkamp A; Hendriks L; Brouwer E; Visser H; Vonkeman HE; Hendrikx J; Jansen TL; Westhovens R; van de Laar MA; van Riel PL
Arthritis Res Ther; 2015 May; 17(1):134. PubMed ID: 25997746
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the efficacies of abatacept and tocilizumab in patients with rheumatoid arthritis by propensity score matching.
Kubo S; Nakayamada S; Nakano K; Hirata S; Fukuyo S; Miyagawa I; Hanami K; Saito K; Tanaka Y
Ann Rheum Dis; 2016 Jul; 75(7):1321-7. PubMed ID: 26245754
[TBL] [Abstract][Full Text] [Related]
18. Risk of serious infections in tocilizumab versus other biologic drugs in patients with rheumatoid arthritis: a multidatabase cohort study.
Pawar A; Desai RJ; Solomon DH; Santiago Ortiz AJ; Gale S; Bao M; Sarsour K; Schneeweiss S; Kim SC
Ann Rheum Dis; 2019 Apr; 78(4):456-464. PubMed ID: 30679153
[TBL] [Abstract][Full Text] [Related]
19. EuroQol-5 dimensions utility gain according to British and Swedish preference sets in rheumatoid arthritis treated with abatacept, rituximab, tocilizumab, or tumour necrosis factor inhibitors: a prospective cohort study from southern Sweden.
Gülfe A; Wallman JK; Kristensen LE
Arthritis Res Ther; 2016 Feb; 18():51. PubMed ID: 26892115
[TBL] [Abstract][Full Text] [Related]
20. Risk of malignancy associated with use of tocilizumab versus other biologics in patients with rheumatoid arthritis: A multi-database cohort study.
Kim SC; Pawar A; Desai RJ; Solomon DH; Gale S; Bao M; Sarsour K; Schneeweiss S
Semin Arthritis Rheum; 2019 Oct; 49(2):222-228. PubMed ID: 30967248
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]